Global Changes in Gene Expression of Barrett's Esophagus Compared to Normal Squamous Esophagus and Gastric Cardia Tissues

Hyland, Paula L.; Hu, Nan; Rotunno, Melissa; Su, Hua; Wang, Chaoyu; Wang, Lemin; Pfeiffer, Ruth M.; Gherman, Barbara; Giffen, Carol; Dykes, Cathy; Dawsey, Sanford M.; Abnet, Christian C.; Johnson, Kathryn M.; Acosta, Ruben D.; Young, Patrick E.; Cash, Brooks D.; Taylor, Philip R.
April 2014
PLoS ONE;Apr2014, Vol. 9 Issue 4, p1
Academic Journal
Background: Barrett's esophagus (BE) is a metaplastic precursor lesion of esophageal adenocarcinoma (EA), the most rapidly increasing cancer in western societies. While the prevalence of BE is increasing, the vast majority of EA occurs in patients with undiagnosed BE. Thus, we sought to identify genes that are altered in BE compared to the normal mucosa of the esophagus, and which may be potential biomarkers for the development or diagnosis of BE. Design: We performed gene expression analysis using HG-U133A Affymetrix chips on fresh frozen tissue samples of Barrett's metaplasia and matched normal mucosa from squamous esophagus (NE) and gastric cardia (NC) in 40 BE patients. Results: Using a cut off of 2-fold and P<1.12E-06 (0.05 with Bonferroni correction), we identified 1324 differentially-expressed genes comparing BE vs NE and 649 differentially-expressed genes comparing BE vs NC. Except for individual genes such as the SOXs and PROM1 that were dysregulated only in BE vs NE, we found a subset of genes (n = 205) whose expression was significantly altered in both BE vs NE and BE vs NC. These genes were overrepresented in different pathways, including TGF-β and Notch. Conclusion: Our findings provide additional data on the global transcriptome in BE tissues compared to matched NE and NC tissues which should promote further understanding of the functions and regulatory mechanisms of genes involved in BE development, as well as insight into novel genes that may be useful as potential biomarkers for the diagnosis of BE in the future.


Related Articles

  • Sulindac Prevents Esophageal Adenocarcinomas Induced by Gastroduodenal Reflux in Rats. Sung Wook Kim; Tae Jung Jang; Ki Hoon Jung; Jung Il Suh // Yonsei Medical Journal;12/31/2008, Vol. 48 Issue 6, p1020 

    Purpose: It is known that cyclooxygenase (COX)-2 expression is increased in Barrett's esophagus and esophageal adenocarcinomas. We studied COX-2 expression and the effect sulindac has on the genesis of Barrett's esophagus and adenocarcinoma in rats undergoing esophagogastroduodenal anastomosis...

  • E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. Evangelou, K.; Kotsinas, A.; Mariolis-Sapsakos, T.; Giannopoulos, A.; Tsantoulis, P. K.; Constantinides, C.; Troupis, T. G.; Salmas, M.; Kyroudis, A.; Kittas, C.; Gorgoulis, V. G. // Journal of Clinical Pathology;May2008, Vol. 61 Issue 5, p601 

    Background: E2F-1 expression is positively associated with tumour growth in oesophageal squamous-cell carcinomas (OSCC), while it exhibits oncosuppressive features in colonic adenocarcinomas (AC). To date there are no data regarding E2F-1 expression and its relationship with tumour kinetics...

  • The usefulness of chromoendoscopy with methylene blue in Barrett’s metaplasia and early esophageal carcinoma. Ormeci, N.; Savas, B.; Coban, S.; Palabıyıkoğlu, M.; Ensari, A.; Kuzu, I.; Kursun, N. // Surgical Endoscopy;Mar2008, Vol. 22 Issue 3, p693 

    Barrett’s esophagus is a condition that is premalignant for adenocarcinoma of the esophagus and the esophagogastric junction. Early detection of Barrett’s metaplasia and dysplasia is very important to decrease the mortality and morbidity from esophageal adenocarcinoma cancer. This...

  • Editorial: Where Are You and How Do We Find You? The Dilemma of Identifying Barrett's Epithelium Before Adenocarcinoma of the Esophagus. Wong, Roy K. H.; Altekruse, Sean F. // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1363 

    The incidence of esophageal adenocarcinoma in white males has been increasing steadily over the past decade. However, attempts to identify the precursor lesion, intestinal metaplasia of the esophagus, or early in-situ cancers have been dismal, with no increase in the diagnosis of early cancers...

  • Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Cen, P.; Correa, A. M.; Le, J. H.; Maru, D.; Anandasabapathy, S.; Liao, Z.; Hofstetter, W. L.; Swisher, S. G.; Komaki, R.; Ross, W. A.; Vaporciyan, A.; Ajani, J. A. // Diseases of the Esophagus;Feb2009, Vol. 22 Issue 1, p32 

    SUMAMRY It remains unclear whether the overall survival (OS) of patients with localized esophageal adenocarcinoma (LEA) with Barrett's esophagus (BE) (Barrett's-positive) and those with LEA without BE (Barrett's-negative) following preoperative chemoradiation is different. Based on the published...

  • Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Becker, L.; Huang, Q.; Mashimo, H. // Diseases of the Esophagus;Feb2010, Vol. 23 Issue 2, p168 

    Lgr5 (leucine-rich-repeat-containing G-protein-coupled receptor 5), a recently discovered intestinal stem cell marker, is expressed in premalignant lesions including Barrett's esophagus (BE) and cancers including colon cancer, ovarian cancer, and hepatocellular carcinoma. It was also recently...

  • Barrett's Esophagus: Where Do We Stand? Al Madi, Majid A. // Saudi Journal of Gastroenterology;Jan2009, Vol. 15 Issue 1, p2 

    Barrett's esophagus (BE) is a precursor for esophageal adenocarcinoma, which has an increased incidence rate over the last few decades. Its importance stems from the poor five-year survival of esophageal adenocarcinoma and current data that suggest a survival benefit when surveillance programs...

  • Barrett's Esophagus on Repeat Endoscopy: Should We Look More Than Once? Rodriguez, Sarah; Mattek, Nora; Lieberman, David; Fennerty, Brian; Eisen, Glenn // American Journal of Gastroenterology;Aug2008, Vol. 103 Issue 8, p1892 

    BACKGROUND: Barrett's esophagus (BE) is the precursor lesion for esophageal adenocarcinoma. The major risk factor for BE is chronic gastroesophageal reflux disease (GERD). Screening patients with longstanding GERD for BE with upper esophagogastroduodenoscopy (EGD) has become the standard...

  • Receipt of Previous Diagnoses and Endoscopy and Outcome From Esophageal Adenocarcinoma: A Population-Based Study With Temporal Trends. Cooper, Gregory S.; Tzyung Doug Kou; Chak, Amitabh // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1356 

    OBJECTIVES:Endoscopic screening of the at-risk population with chronic gastroesophageal reflux disease (GERD) for the presence of intestinal metaplasia or Barrett's esophagus has been suggested as a method to reduce mortality from esophageal adenocarcinoma. There are only limited data regarding...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics